Singapore-headquartered biotechnology company ASLAN Pharmaceuticals, which focuses on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has concluded an initial public offering (IPO) of common shares via public lottery.
The company on Wednesday issued 2,602,000 shares for the public draw at the offer price of NT$68.92. The results of the public lottery saw 76,377 qualified deals with a lot winning rate of 3.4 per cent. The shares were 29.4 times oversubscribed.
